Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Cristan Farmer, Jessica R. Gilbert, Ruin Moaddel, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1398-1404
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei Yan, Lijia Chang, Kenji Hashimoto
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 559-573
Open Access | Times Cited: 178
Ketamine: A tale of two enantiomers
Luke A. Jelen, Allan H. Young, James Stone
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 109-123
Open Access | Times Cited: 162
The role of dissociation in ketamine’s antidepressant effects
Elizabeth D. Ballard, Carlos A. Zarate
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 140
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
Yazen Alnefeesi, David Chen‐Li, Ella Krane, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 693-709
Closed Access | Times Cited: 105
Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
Samuel Kohtala
Pharmacological Reports (2021) Vol. 73, Iss. 2, pp. 323-345
Open Access | Times Cited: 90
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 2, pp. 763-791
Open Access | Times Cited: 75
Ketamine and its metabolites: Potential as novel treatments for depression
Kai Zhang, Yitan Yao, Kenji Hashimoto
Neuropharmacology (2022) Vol. 222, pp. 109305-109305
Closed Access | Times Cited: 57
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
Gustavo C. Medeiros, Todd D. Gould, William L. Prueitt, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 9, pp. 3658-3669
Open Access | Times Cited: 39
Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Songbai Xu, Xiaoxiao Yao, Bingjin Li, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 38
Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression
Jared M. Kopelman, Timothy A. Keller, Benjamin Panny, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Jordi Bonaventura, Juan L. Gomez, Meghan L. Carlton, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 10, pp. 4144-4156
Open Access | Times Cited: 31
BDNF receptor TrkB as the mediator of the antidepressant drug action
Plínio Casarotto, Juzoh Umemori, Eero Ċastrén
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 28
Beyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Lindsay P. Cameron, Joseph Benetatos, Vern Lewis, et al.
Journal of Neuroscience (2023) Vol. 43, Iss. 45, pp. 7472-7482
Open Access | Times Cited: 21
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
Vern Lewis, Gareth M. Rurak, Natalina Salmaso, et al.
Trends in Neurosciences (2024) Vol. 47, Iss. 3, pp. 195-208
Open Access | Times Cited: 7
Fronto-limbic neuroimaging biomarkers for diagnosis and prediction of treatment responses in major depressive disorder
Chien‐Han Lai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 107, pp. 110234-110234
Closed Access | Times Cited: 42
Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series
Hewa Artin, Sean Bentley, Eamonn Mehaffey, et al.
EClinicalMedicine (2022) Vol. 48, pp. 101439-101439
Open Access | Times Cited: 23
Plasticity of synapses and reward circuit function in the genesis and treatment of depression
Scott M. Thompson
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 90-103
Closed Access | Times Cited: 23
Hydroxynorketamine, but not ketamine, acts via α7 nicotinic acetylcholine receptor to control presynaptic function and gene expression
Debarpan Guhathakurta, Aneta Petrušková, Enes Yağız Akdaş, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial
Sumra Sajid, Hanga Galfalvy, John G. Keilp, et al.
The International Journal of Neuropsychopharmacology (2024) Vol. 27, Iss. 4
Open Access | Times Cited: 4
Examining memory reconsolidation as a mechanism of nitrous oxide’s antidepressant action
Ella Williams, Uršulė Taujanskaitė, Sunjeev K. Kamboj, et al.
Neuropsychopharmacology (2025) Vol. 50, Iss. 4, pp. 609-617
Open Access
Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches
Aline Silva de Miranda, Eliana Cristina de Brito Toscano, Venugopal Reddy Venna, et al.
Expert Opinion on Drug Discovery (2025), pp. 1-15
Closed Access
Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depression
Kasper Recourt, Joop van Gerven, Nadieh Drenth, et al.
Frontiers in Neuroscience (2025) Vol. 19
Open Access
PROPHYLACTIC KETAMINE: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS
Astrid M. Cardona-Acosta, Lyonna F. Parise, Carlos A. Bolaños‐Guzmán, et al.
Biological Psychiatry (2025)
Closed Access
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines
Jaclyn N. Highland, Patrick J. Morris, Kylie M. Konrath, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 4, pp. 510-523
Open Access | Times Cited: 19
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Courtney M. Vecera, Alan C. Courtes, Gregory Jones, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1572-1572
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top